Posted innews Oncology Pathology & Lab Medicine
Beyond Detection: How ctDNA Dynamics Predict Treatment Success in Advanced Breast Cancer
The plasmaMATCH trial establishes ctDNA testing as a highly accurate tool for directing targeted therapies in advanced breast cancer. New data reveal that baseline ctDNA levels and early on-treatment dynamics serve as powerful prognostic markers and potential surrogate endpoints for clinical outcomes.